# Study to Evaluate Effectiveness of Aranesp®

> **NCT00117130** · PHASE4 · COMPLETED · sponsor: **Amgen**

## Conditions studied

- Kidney Disease

## Interventions

- **DRUG:** Aranesp®

## Key facts

- **NCT ID:** NCT00117130
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2011-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00117130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00117130, "Study to Evaluate Effectiveness of Aranesp®". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT00117130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*